Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Income from Continuing Operations rose 12040.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 5849.86%. This contributed to the annual value of -$87.9 million for FY2024, which is 4618.49% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Income from Continuing Operations is $2.9 million, which was up 12040.74% from -$5.9 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Income from Continuing Operations registered a high of $57.3 million during Q4 2021, and its lowest value of -$74.0 million during Q2 2023.
  • For the 5-year period, Mirum Pharmaceuticals' Income from Continuing Operations averaged around -$25.7 million, with its median value being -$26.9 million (2022).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 25352.45% in 2021, then tumbled by 17500.93% in 2023.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Income from Continuing Operations stood at $57.3 million in 2021, then tumbled by 163.6% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then skyrocketed by 33.28% to -$23.8 million in 2024, then skyrocketed by 112.21% to $2.9 million in 2025.
  • Its Income from Continuing Operations was $2.9 million in Q3 2025, compared to -$5.9 million in Q2 2025 and -$14.7 million in Q1 2025.